Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
275,000,000
-
Total 13F shares
-
140,148,555
-
Share change
-
+10,018,673
-
Total reported value
-
$402,080,424
-
Put/Call ratio
-
147%
-
Price per share
-
$2.87
-
Number of holders
-
106
-
Value change
-
+$33,453,660
-
Number of buys
-
63
-
Number of sells
-
41
Institutional Holders of Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) as of Q1 2024
As of 31 Mar 2024,
Taysha Gene Therapies, Inc. - Common Stock, par value $0.00001 per share (TSHA) was held by
106 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
140,148,555 shares.
The largest 10 holders included
FMR LLC, Avoro Capital Advisors LLC, RTW INVESTMENTS, LP, RA CAPITAL MANAGEMENT, L.P., VR Adviser, LLC, VANGUARD GROUP INC, MORGAN STANLEY, BAKER BROS. ADVISORS LP, TYBOURNE CAPITAL MANAGEMENT (HK) LTD, and Artal Group S.A..
This page lists
106
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.